Larry Lasky founded Cleave Therapeutics, Inc. Presently, he is Partner at The Column Group LLC.
He is also on the board of Carmot Therapeutics, Inc., eFFECTOR Therapeutics, Inc. and Accent Therapeutics, Inc. and Partner at U.S. Venture Partners X LP.
Dr. Lasky previously was Principal at NCI, Inc., Partner at Latterell Venture Partners, Partner at Presidio Management Group, Inc., Scientist at Genentech, Inc., Principal at National Institutes of Health, Scientist at Genentech Ventures and Director at Cleave Therapeutics, Inc.
Dr. Lasky received an undergraduate degree and a doctorate from the University of California, Los Angeles.